- Trial phase
- Phase 1
- Time to market
- Unknown, Phase 1 dosing only began June 2026; Phase 2 anticipated 2027, so approval (if trials succeed) is realistically many years away (early-to-mid 2030s).
- Why 2/10
- MGL-2086 is a Phase 1 program with no hard, dated binary in the next ~12 months, SAD/MAD dosing runs through 2026 and data will only inform a Phase 2 combination study (with resmetirom) anticipated for 2027, and it is a small part of a commercial company whose share price is driven by Rezdiffra sales, so the score sits at the bottom of the scale (0-2).
Do not trade MDGL on MGL-2086, there is no dated readout to trade; near-term price action will be driven by Rezdiffra's commercial ramp and the 2027 MAESTRO F4c cirrhosis outcomes readout. Watch for (1) any early Phase 1 SAD/MAD data release for MGL-2086 (likely 2027), (2) FDA feedback on the Rezdiffra/MGL-2086 Phase 2 combo design, and (3) progress of rival oral GLP-1s (notably Lilly's orforglipron, the molecule this is derived from), which caps the strategic upside.
Price Chart
Executive Summary
MGL-2086 (formerly SYH2086) is an oral small-molecule GLP-1 receptor agonist, a derivative of Eli Lilly's orforglipron, that Madrigal exclusively licensed from China's CSPC Pharmaceutical Group in July 2025 for $120M upfront and up to $2B in milestones plus royalties, to combine with its approved MASH drug Rezdiffra. Dosing in the Phase 1 single-ascending-dose trial began in June 2026, on schedule, with Phase 2 combination data targeted for 2027. It is a strategically sensible but very early, unproven program at a commercial company whose stock (MDGL, ~$467 as of July 31, 2026) is driven by Rezdiffra's sales ramp, so MGL-2086 itself carries no near-term binary catalyst.
How It Works
MGL-2086 is a pill that mimics the natural gut hormone GLP-1, the same biological target as popular injected weight-loss drugs like Ozempic/Wegovy. It suppresses appetite, slows digestion and improves metabolic markers. Madrigal's plan is to pair it with its approved liver drug Rezdiffra so MASH (fatty liver disease) patients get weight/metabolic benefit plus direct liver benefit in one daily pill.
Trial Status
Phase 1 single ascending dose (SAD) trial dosing initiated June 2026, as part of the Rezdiffra/MGL-2086 combination program in MASH; SAD and multiple ascending dose (MAD) studies ongoing through 2026, with results expected to inform a Phase 2 combination study with resmetirom anticipated in 2027. No efficacy data reported yet.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 SAD/MAD data for MGL-2086 (no firm date; expected to inform Phase 2 design, likely 2027)
- FDA consultations on Phase 2 combination trial design for Rezdiffra/MGL-2086 (2026)
- Phase 2 combination trial initiation, anticipated 2027
- Context (not MGL-2086): Rezdiffra Phase 3 MAESTRO F4c cirrhosis outcomes readout expected 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MADRIGAL PHARMACEUTICALS, INC. 8-K MDGL ·Originating report